Laura Chico
Stock Analyst at Wedbush
(3.69)
# 805
Out of 5,111 analysts
233
Total ratings
46.58%
Success rate
8.28%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics | Maintains: Outperform | $31 → $30 | $17.34 | +73.01% | 10 | Dec 11, 2025 | |
| VERA Vera Therapeutics | Maintains: Neutral | $23 → $33 | $49.21 | -32.94% | 9 | Dec 11, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $42 → $47 | $33.03 | +42.29% | 8 | Dec 10, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Underperform | $77 → $83 | $276.40 | -69.97% | 9 | Dec 5, 2025 | |
| PHVS Pharvaris | Maintains: Outperform | $27 → $30 | $23.90 | +25.52% | 8 | Nov 13, 2025 | |
| MAZE Maze Therapeutics | Maintains: Outperform | $35 → $36 | $39.71 | -9.34% | 2 | Nov 7, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $35 → $32 | $23.94 | +33.67% | 11 | Nov 7, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $44 → $46 | $41.92 | +9.73% | 10 | Nov 6, 2025 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $22 → $32 | $32.98 | -2.97% | 8 | Nov 5, 2025 | |
| ATXS Astria Therapeutics | Downgrades: Neutral | $28 → $13 | $12.92 | +0.62% | 10 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $11 | $3.92 | +180.61% | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $8 | $5.47 | +46.25% | 12 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $18 | $15.25 | +18.03% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $14 | $5.71 | +145.18% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $43 | $43.60 | -1.38% | 9 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $34.76 | -7.94% | 12 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $3.79 | +31.93% | 6 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $14 | $6.20 | +125.81% | 14 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $137 → $141 | $154.06 | -8.48% | 10 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $34 | $36.23 | -6.16% | 13 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $7.59 | +137.15% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $130 | $119.73 | +8.58% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $121 | $175.74 | -31.15% | 18 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $17.03 | -76.51% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $1.56 | +92.31% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $24.56 | +18.08% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $4.36 | +60.55% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.77 | +1,334.07% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $9.12 | -45.18% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $52.12 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $5.76 | -13.19% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $11.28 | +1,216.49% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $9.48 | +7,494.94% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $220.10 | +27.21% | 1 | Apr 21, 2017 |
Denali Therapeutics
Dec 11, 2025
Maintains: Outperform
Price Target: $31 → $30
Current: $17.34
Upside: +73.01%
Vera Therapeutics
Dec 11, 2025
Maintains: Neutral
Price Target: $23 → $33
Current: $49.21
Upside: -32.94%
Viridian Therapeutics
Dec 10, 2025
Maintains: Outperform
Price Target: $42 → $47
Current: $33.03
Upside: +42.29%
Praxis Precision Medicines
Dec 5, 2025
Maintains: Underperform
Price Target: $77 → $83
Current: $276.40
Upside: -69.97%
Pharvaris
Nov 13, 2025
Maintains: Outperform
Price Target: $27 → $30
Current: $23.90
Upside: +25.52%
Maze Therapeutics
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $36
Current: $39.71
Upside: -9.34%
Edgewise Therapeutics
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $23.94
Upside: +33.67%
Dianthus Therapeutics
Nov 6, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $41.92
Upside: +9.73%
Stoke Therapeutics
Nov 5, 2025
Maintains: Outperform
Price Target: $22 → $32
Current: $32.98
Upside: -2.97%
Astria Therapeutics
Oct 15, 2025
Downgrades: Neutral
Price Target: $28 → $13
Current: $12.92
Upside: +0.62%
Sep 30, 2025
Maintains: Outperform
Price Target: $15 → $11
Current: $3.92
Upside: +180.61%
Sep 30, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $5.47
Upside: +46.25%
Aug 14, 2025
Maintains: Outperform
Price Target: $17 → $18
Current: $15.25
Upside: +18.03%
Aug 13, 2025
Maintains: Outperform
Price Target: $17 → $14
Current: $5.71
Upside: +145.18%
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $43.60
Upside: -1.38%
Aug 7, 2025
Maintains: Outperform
Price Target: $30 → $32
Current: $34.76
Upside: -7.94%
Aug 6, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $3.79
Upside: +31.93%
Aug 5, 2025
Maintains: Outperform
Price Target: $13 → $14
Current: $6.20
Upside: +125.81%
Jul 31, 2025
Maintains: Outperform
Price Target: $137 → $141
Current: $154.06
Upside: -8.48%
Jul 14, 2025
Maintains: Neutral
Price Target: $35 → $34
Current: $36.23
Upside: -6.16%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $7.59
Upside: +137.15%
Jun 18, 2025
Reiterates: Neutral
Price Target: $130
Current: $119.73
Upside: +8.58%
Jun 12, 2025
Reiterates: Neutral
Price Target: $121
Current: $175.74
Upside: -31.15%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $17.03
Upside: -76.51%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $1.56
Upside: +92.31%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $24.56
Upside: +18.08%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $4.36
Upside: +60.55%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.77
Upside: +1,334.07%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $9.12
Upside: -45.18%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $52.12
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $5.76
Upside: -13.19%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $11.28
Upside: +1,216.49%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $9.48
Upside: +7,494.94%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $220.10
Upside: +27.21%